Home » Stocks » Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. (DFFN)

Stock Price: $0.830 USD -0.013 (-1.57%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.810 -0.020 (-2.41%) Oct 21, 5:27 PM

Stock Price Chart

Key Info

Market Cap 53.12M
Revenue (ttm) n/a
Net Income (ttm) -12.24M
Shares Out 64.00M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.830
Previous Close $0.843
Change ($) -0.013
Change (%) -1.57%
Day's Open 0.854
Day's Range 0.805 - 0.858
Day's Volume 405,981
52-Week Range 0.211 - 1.600

More Stats

Market Cap 53.12M
Enterprise Value 27.75M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 64.00M
Float 63.92M
EPS (basic) -0.52
EPS (diluted) -0.54
FCF / Share -0.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 853,648
Short Ratio 0.62
Short % of Float 1.34%
Beta 2.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.61
Revenue n/a
Operating Income -12.63M
Net Income -12.24M
Free Cash Flow -11.24M
Net Cash 25.37M
Net Cash / Share 0.40
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.74%
ROE -49.91%
ROIC -4,933.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.50*
Low
3.50
Current: $0.830
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-------0.370.570.04
Revenue Growth--------34.35%1319.48%-
Gross Profit-------0.14-1.74-0.17
Operating Income-11.55-18.96-11.35-18.37-6.41-14.61-9.07-11.79-16.43-4.70
Net Income-11.80-18.37-1.36-18.04-6.72-14.35-2.64-6.87-22.64-8.41
Shares Outstanding6.713.240.830.680.170.100.020.010.01-
Earnings Per Share-1.76-8.21-29.11-26.40-38.40-149.99-149.99-1,223.94-3,899.81-2,099.90
Operating Cash Flow-9.86-10.77-12.33-10.77-5.19-9.03-1.18-4.31-12.02-1.98
Capital Expenditures---0.45--0.04-0.05---0.12-0.01
Free Cash Flow-9.86-10.77-12.78-10.77-5.23-9.08-1.18-4.31-12.15-1.99
Cash & Equivalents14.187.998.901.552.0021.880.250.310.100.04
Total Debt0.25-0.552.431.24-1.874.000.562.12
Net Cash / Debt13.937.998.35-0.880.7521.88-1.61-3.69-0.46-2.08
Assets24.1118.2026.1517.482.2842.7818.342.453.675.58
Liabilities3.982.594.928.302.324.6111.8820.8519.685.56
Book Value20.1315.6121.239.18-0.0438.176.46-18.39-16.030.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Diffusion Pharmaceuticals, Inc.
Country United States
Employees 10
CEO Robert J. Cobuzzi

Stock Information

Ticker Symbol DFFN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DFFN

Description

Diffusion Pharmaceuticals, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.